NASDAQ:QDEL QuidelOrtho (QDEL) Stock Forecast, Price & News $86.16 +0.51 (+0.60%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$85.92▼$87.0050-Day Range$84.72▼$94.1652-Week Range$66.88▼$108.35Volume217,417 shsAverage Volume435,747 shsMarket Capitalization$5.74 billionP/E Ratio47.34Dividend YieldN/APrice Target$123.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability QuidelOrtho MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside43.7% Upside$123.83 Price TargetShort InterestBearish4.25% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment1.19Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth8.69%From $5.18 to $5.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsMedical Sector119th out of 983 stocksDiagnostic Substances Industry3rd out of 15 stocks 3.4 Analyst's Opinion Consensus RatingQuidelOrtho has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $123.83, QuidelOrtho has a forecasted upside of 43.7% from its current price of $86.16.Amount of Analyst CoverageQuidelOrtho has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.25% of the outstanding shares of QuidelOrtho have been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in QuidelOrtho has recently increased by 1.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.Environmental SustainabilityThe Environmental Impact score for QuidelOrtho is -2.61. Previous Next 2.9 News and Social Media Coverage News SentimentQuidelOrtho has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for QuidelOrtho this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -84% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions95.21% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for QuidelOrtho are expected to grow by 8.69% in the coming year, from $5.18 to $5.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is 47.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.41.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is 47.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 138.67.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About QuidelOrtho (NASDAQ:QDEL) StockQuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.Read More Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address QDEL Stock News HeadlinesMay 30, 2023 | americanbankingnews.comBrokerages Set QuidelOrtho Co. (NASDAQ:QDEL) Target Price at $123.83May 23, 2023 | finance.yahoo.comQuidelOrtho to Participate in William Blair 43rd Annual Growth Stock ConferenceJune 3, 2023 | Stansberry Research (Ad)The gold catalyst we've waited forBecause even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.May 22, 2023 | americanbankingnews.comStockNews.com Begins Coverage on QuidelOrtho (NASDAQ:QDEL)May 12, 2023 | msn.comQuidelOrtho's Return on Invested Capital OverviewMay 7, 2023 | americanbankingnews.comQuidelOrtho Co. (NASDAQ:QDEL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 5, 2023 | americanbankingnews.comBrokerages Set QuidelOrtho Co. (NASDAQ:QDEL) Price Target at $123.83May 3, 2023 | finance.yahoo.comQuidelOrtho Reports First Quarter 2023 Financial ResultsJune 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 3, 2023 | seekingalpha.comQuidelOrtho Corporation 2023 Q1 - Results - Earnings Call PresentationMay 1, 2023 | americanbankingnews.comQuidelOrtho (QDEL) to Release Quarterly Earnings on WednesdayApril 22, 2023 | seekingalpha.comQuidelOrtho: 5x Earnings Is Borderline Offensive, Rate Buy At 20xApril 18, 2023 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on QuidelOrtho (QDEL)April 18, 2023 | uk.finance.yahoo.comQuidelOrtho (QDEL) Soars 5.0%: Is Further Upside Left in the Stock?April 15, 2023 | markets.businessinsider.comRBC Capital Remains a Buy on QuidelOrtho (QDEL)April 15, 2023 | msn.comWhy QuidelOrtho Stock Popped by 5% on FridayApril 14, 2023 | markets.businessinsider.comQuidelOrtho (QDEL) Receives a Buy from Craig-HallumApril 13, 2023 | msn.comWhy QuidelOrtho Stock Is Rising After HoursApril 13, 2023 | finance.yahoo.comQuidelOrtho Reports Preliminary Revenue Results for the First Quarter 2023April 10, 2023 | americanbankingnews.comQuidelOrtho Co. (NASDAQ:QDEL) Receives $123.83 Average Target Price from BrokeragesMarch 28, 2023 | finance.yahoo.comQuidelOrtho Announces the Formation of the International QuidelOrtho Women’s Leadership Network (QWLN)March 28, 2023 | finance.yahoo.comQuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 36% Below Their Intrinsic Value EstimateMarch 8, 2023 | finance.yahoo.comQuidelOrtho Receives De Novo FDA Authorization for Sofia® 2 SARS Antigen+ FIAMarch 2, 2023 | finance.yahoo.comQuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor ConferenceMarch 1, 2023 | benzinga.comImageMover and QuidelOrtho Partner to Simplify Test-to-Treat Process for PharmaciesFebruary 27, 2023 | finance.yahoo.comQuidelOrtho Full Year 2022 Earnings: EPS Beats Expectations, Revenues LagFebruary 18, 2023 | finance.yahoo.comQuidelOrtho Corporation Just Missed Revenue By 8.0%: Here's What Analysts Think Will Happen NextSee More Headlines QDEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QDEL Company Calendar Last Earnings11/04/2021Today6/02/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:QDEL CUSIP74838J10 CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,000Year Founded1979Price Target and Rating Average Stock Price Forecast$123.83 High Stock Price Forecast$173.00 Low Stock Price Forecast$86.00 Forecasted Upside/Downside+43.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.82 Trailing P/E Ratio47.34 Forward P/E Ratio16.63 P/E GrowthN/ANet Income$548.70 million Net Margins3.78% Pretax Margin5.64% Return on Equity10.25% Return on Assets5.73% Debt Debt-to-Equity Ratio0.48 Current Ratio1.65 Quick Ratio1.07 Sales & Book Value Annual Sales$3.27 billion Price / Sales1.76 Cash Flow$18.45 per share Price / Cash Flow4.67 Book Value$74.99 per share Price / Book1.15Miscellaneous Outstanding Shares66,630,000Free Float64,834,000Market Cap$5.74 billion OptionableOptionable Beta0.29 Social Links Key ExecutivesDouglas C. BryantPresident, Chief Executive Officer & DirectorRobert Joseph BujarskiChief Operating Officer & Executive Vice PresidentJoseph Michael BuskyChief Financial OfficerLouise BrandyChief Information OfficerWerner KrollSenior Vice President-Research & DevelopmentKey CompetitorsNeogenNASDAQ:NEOGLantheusNASDAQ:LNTHIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNCelldex TherapeuticsNASDAQ:CLDXView All CompetitorsInstitutional OwnershipProShare Advisors LLCSold 691 shares on 5/26/2023Ownership: 0.005%Ameriprise Financial Inc.Bought 10,345 shares on 5/22/2023Ownership: 0.124%Putnam Investments LLCBought 45,311 shares on 5/22/2023Ownership: 0.068%JPMorgan Chase & Co.Sold 2,194 shares on 5/18/2023Ownership: 1.801%New York State Common Retirement FundSold 60,049 shares on 5/18/2023Ownership: 0.162%View All Institutional Transactions QDEL Stock - Frequently Asked Questions Should I buy or sell QuidelOrtho stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QDEL shares. View QDEL analyst ratings or view top-rated stocks. What is QuidelOrtho's stock price forecast for 2023? 5 brokers have issued 1 year target prices for QuidelOrtho's shares. Their QDEL share price forecasts range from $86.00 to $173.00. On average, they anticipate the company's stock price to reach $123.83 in the next twelve months. This suggests a possible upside of 43.7% from the stock's current price. View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts. How have QDEL shares performed in 2023? QuidelOrtho's stock was trading at $85.67 on January 1st, 2023. Since then, QDEL shares have increased by 0.6% and is now trading at $86.16. View the best growth stocks for 2023 here. When is QuidelOrtho's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our QDEL earnings forecast. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) posted its quarterly earnings results on Thursday, November, 4th. The company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.52 by $1.84. The company earned $509.70 million during the quarter, compared to analysts' expectations of $344.25 million. QuidelOrtho had a trailing twelve-month return on equity of 10.25% and a net margin of 3.78%. QuidelOrtho's revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.68 earnings per share. What ETFs hold QuidelOrtho's stock? ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), First Trust Health Care AlphaDEX Fund (FXH), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Burney U.S. Factor Rotation ETF (BRNY) and Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG). What guidance has QuidelOrtho issued on next quarter's earnings? QuidelOrtho updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $5.15-$5.70 for the period, compared to the consensus earnings per share estimate of $5.23. The company issued revenue guidance of $2.87 billion-$3.18 billion, compared to the consensus revenue estimate of $2.95 billion. What is Doug Bryant's approval rating as QuidelOrtho's CEO? 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM). What is QuidelOrtho's stock symbol? QuidelOrtho trades on the NASDAQ under the ticker symbol "QDEL." Who are QuidelOrtho's major shareholders? QuidelOrtho's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.50%), ArrowMark Colorado Holdings LLC (4.93%), State Street Corp (2.31%), JPMorgan Chase & Co. (1.80%), Neuberger Berman Group LLC (1.73%) and Alyeska Investment Group L.P. (1.72%). Insiders that own company stock include Charles P Slacik, Douglas C Bryant, Edward L Michael, Mary Lake Ph D Polan, Matthew Strobeck, Michael Donald Jr Abney, Randall J Steward, Werner Kroll, William J Ferenczy and William J Ferenczy. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is QuidelOrtho's stock price today? One share of QDEL stock can currently be purchased for approximately $86.16. How much money does QuidelOrtho make? QuidelOrtho (NASDAQ:QDEL) has a market capitalization of $5.74 billion and generates $3.27 billion in revenue each year. The company earns $548.70 million in net income (profit) each year or $1.82 on an earnings per share basis. How many employees does QuidelOrtho have? The company employs 7,000 workers across the globe. How can I contact QuidelOrtho? QuidelOrtho's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The official website for the company is www.quidel.com. The company can be reached via phone at (800) 874-1517, via email at rargueta@quidel.com, or via fax at 858-453-4338. This page (NASDAQ:QDEL) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.